Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.

Autor: Patel DR; Clinical Services, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Urva S; Global PK/PD & Pharmacometrics, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Ho S; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Buckman CJ; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Ma Y; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Lim J; Global PK/PD & Pharmacometrics - SG, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Sissons SE; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Zuniga MS; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Philips D; Clinical Pharmacology, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Cox K; Translational Sciences - Autoimmunity, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA., Dairaghi DJ; Immunology Discovery Research, Lilly Corporate Center, Eli Lilly and Co, Indianapolis, Indiana, USA.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2021 May; Vol. 14 (3), pp. 1037-1048. Date of Electronic Publication: 2021 Feb 13.